Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementHighmark Blueshield NENY Opioid Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentHighmark Blueshield NenyPolicy N/A

    Medication Prior Authorization for Opioids

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and requirements for prior authorization of opioid medications for Highmark BlueShield members in North Carolina; governs what provider-completed documentation and clinical information are required to request authorization.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyMedication Prior Authorization for Opioids
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form (separate form per medication) by fax to 1-866-240-8123 or by mail with required clinical documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1separate form required per medication
    1-866-240-8123fax number to submit form

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    30/90
    requested supply day options
    PDMPcontrolled substance history review

    Coverage Criteria

    Initial Authorization Criteria

    Covered when ALL of the following are met:

    Indication: Member has one of the listed indications: chronic pain; pain associated with cancer; pain associated with end-of-life or palliative care; sickle cell anemia–related pain; resides in a long-term care facility; documented acute pain where other agents would be insufficient; or pain related to a terminal illness.
    Severity and necessity: Member has pain severe enough to require daily, around-the-clock, long-term opioid treatment and the member is not opioid naive.
    Dose justification: Based on the member's clinical circumstances, the prescribed amount of opioid is warranted to adequately manage the member's pain (prescriber indicates Yes).
    Safety checks and monitoring: Controlled substance prescription history has been checked using the state PDMP; the member or parent/guardian has been educated on opioid risks; and there is an ongoing monitoring plan to identify and address drug–drug interactions between the requested opioid and opioid potentiators (e.g., gabapentin, pregabalin, benzodiazepines, sedative‑hypnotics).

    If the provider selects None of the above on the clinical information section, the form indicates that the member does not have any of the documented indications that support opioid therapy (for example: chronic pain, cancer-related pain, end-of-life/palliative care pain, sickle cell pain, long-term care residency, documented acute pain where other agents would be insufficient, or pain related to a terminal illness). In that situation, clinical indications supporting opioid use are not documented on the form and authorization is not supported by the stated criteria.

    Requests may be considered not medically necessary or may be denied when the submission lacks required clinical information. Examples include incomplete documentation answering whether the prescribed opioid amount is warranted for the member's clinical circumstances, absence of an ongoing monitoring plan for drug–drug interactions (for example with gabapentin, pregabalin, benzodiazepines, or sedative‑hypnotics), or missing medication history showing prior therapies tried and failed. The form also states that authorization does not guarantee payment.

    Coding and Supply Options

    Diagnosis codes requested on formICD-10
    ICD-10Diagnosis and/or ICD-10 code(s) (exact codes to be provided by prescriber)
    Supply length options
    Allowed supply lengths30 days or 90 days (other supply length may be provided if specified on the form)
    Alternate optionPrescriber may specify 'Other' supply day on the form to request a different days' supply
    Form field locationRequested Supply Day field on the Medication Information section lists 30 days, 90 days, and Other

    Provider Actions and Submission Requirements

    Prior Authorization

    Submit prior authorization by fax or mail; one form per medication

    Prior authorization requests must be submitted using the completed Medication Prior Authorization form. Fax the completed form and all clinical documentation to 1-866-240-8123 or mail the form to Clinical Services, 120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222. Submit a separate form for each medication.

    • Fax completed form and clinical documentation to 1-866-240-8123
    • Or mail to Clinical Services, 120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222
    • Submit a separate form for each medication
    Step Therapy

    Document evaluation of at least one conservative therapy

    The form requires documentation that at least one conservative therapy was evaluated prior to opioid authorization, including non-opioid medications (NSAIDs, acetaminophen, TCAs, SNRIs, anticonvulsants), exercise/physical therapy, weight loss, or cognitive behavioral therapy.

    Conservative Treatment Requirements

    Conservative Therapy Evaluation

    At least one of the following conservative therapies must be indicated on the form:

    Conservative therapy options: At least one of the following has been evaluated: non-opioid medications (NSAIDs, acetaminophen, tricyclic antidepressants, SNRIs, anticonvulsants); exercise therapy or physical therapy; weight loss; or cognitive behavioral therapy (CBT).

    Provider must indicate evaluation on the form.

    Definitions and Monitoring Considerations

    Opioid candidate indications
    Chronic painThe member has chronic pain
    Cancer-related painThe member has pain associated with cancer (provide cancer diagnosis)
    End-of-life/palliative careThe member has pain associated with end-of-life care or palliative care
    Sickle cell painThe member has pain associated with sickle cell anemia
    Long-term care residentThe member resides in a long-term care facility
    Other qualifying conditionsDocumented acute pain where other agents are insufficient, or pain related to a terminal illness

    Background

    This prior‑authorization form is used to document the clinical rationale and safety steps when requesting opioid therapy for members. It supports opioid use for a range of situations including chronic pain, pain associated with cancer, end‑of‑life or palliative care pain, sickle cell pain, members who reside in long‑term care facilities, documented acute pain where other agents would be insufficient, and pain related to a terminal illness. The form captures severity (need for daily, around‑the‑clock, long‑term opioid treatment), prior conservative therapies evaluated, PDMP review, patient/guardian education, and other monitoring and safety considerations required for authorization.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyMedication Prior Authorization for Opioids
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form (separate form per medication) by fax to 1-866-240-8123 or by mail with required clinical documentation.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Supply OptionsProvider Actions and Submission RequirementsConservative Treatment RequirementsDefinitions and Monitoring ConsiderationsBackground
    • Non-opioid medications (e.g., NSAIDs, acetaminophen, tricyclic antidepressants, SNRIs, anticonvulsants) evaluated
    • Exercise therapy or physical therapy evaluated
    • Weight loss or cognitive behavioral therapy evaluated
    Documentation Required

    Complete all required form fields and include supporting clinical documentation

    Providers must complete all required patient and provider fields on the form, including medication name, strength, requested quantity, requested supply day (30 days, 90 days, or other), directions, and diagnosis with ICD-10 code(s); include clinical information such as pain type, prior therapies tried/failed, PDMP check, monitoring plan, hospice status if applicable, and the prescribing physician’s signature and date.

    • Medication information: name, strength, requested quantity, requested supply day (30 days, 90 days, or other), directions
    • Diagnosis and/or ICD-10 code(s)
    • Clinical information: pain type/indication, prior therapies attempted, PDMP check, monitoring plan for drug-drug interactions, hospice status if applicable
    • Provider information: physician name, NPI, contact info, physician signature and date
    • Include supporting clinical documentation when faxing or mailing
    Denial Risk

    Incomplete or inaccurate information may lead to denial; authorization not a payment guarantee

    Incomplete, inaccurate, or missing information on the form may result in denial of the request; authorization, if granted, does not guarantee payment and payment is subject to member eligibility.

    • Ensure all information is true, accurate, and complete to avoid denial
    • Authorization does not guarantee payment; payment remains subject to member eligibility
    Opioid monitoring considerations
    PDMP checkThe member's history of controlled substance prescriptions must be checked using the state prescription drug monitoring program (PDMP)
    Monitoring plan for interactionsAn ongoing monitoring plan must be documented to identify and address drug-drug interactions between the requested opioid and opioid potentiators (e.g., gabapentin, pregabalin, benzodiazepines, sedative-hypnotics)
    Education and safeguardsMember or parent/guardian must be educated on potential adverse effects, including risk of misuse, abuse, and addiction
    Warranted amount justificationDocumentation must state whether the prescribed opioid amount is warranted based on the member's clinical circumstances